Remicade (infliximab) Prior-Authorization Guide: Policies, Codes & Access Insights
Remicade (infliximab) is a tumor-necrosis-factor-α (TNF-α) inhibitor infused to control autoimmune conditions such as rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Because of its high acquisition cost and the widespread availability of lower-priced biosimilars, U.S. payers impose stringent prior-authorization (PA) and step-therapy rules. This guide summarizes today’s PA requirements, coding details and payer-specific nuances to help providers, infusion operators and health-tech teams keep therapy on schedule.
💉 Drug Overview
| Attribute | Details |
|---|---|
| Brand | Remicade |
| Generic / Biosimilars | Infliximab (remicade originator); Avsola, Inflectra, Renflexis (biosimilars) |
| Route | Intravenous infusion (2 h) |
| Typical Adult Doses | 3 mg/kg (RA) – 5 mg/kg (IBD/psoriasis) at week 0, 2, 6 then q8w |
| Specialty Drug | Yes |
| Core Indications | - Rheumatoid arthritis (with methotrexate) - Crohn’s disease (adult & pediatric) - Ulcerative colitis (adult & pediatric) - Psoriatic arthritis - Plaque psoriasis - Ankylosing spondylitis |
🧾 Coding & Billing
| Code type | Code | Notes |
|---|---|---|
| HCPCS | J1745 – Injection, infliximab, 10 mg | Bill 1 unit = 10 mg |
| NDC examples | 00006-7147-02 (100-mg vial), 00006-4300-02 (Remicade single-use vial) | Biosimilars carry unique NDCs |
| CMS unit guidance | Round up partial vials, append JW modifier to discarded amount | See CMS LCD/LCA for wastage rules |
🏥 Prior-Authorization Criteria by Major Payers
Tip: Nearly every commercial and Medicare Advantage plan prefers a biosimilar first; originator Remicade usually requires documented failure or intolerance.
| Payer | Key PA Elements | Renewal Window |
|---|---|---|
| Aetna | Requires documented TNF-α–inhibitor step-therapy unless patient already stable on Remicade; TB/viral-hepatitis screening mandatory. | 12 months (chronic dx) |
| UnitedHealthcare | Prefers Inflectra or Avsola; patients already on Remicade must switch or show medical necessity (all indications). | 12 months; earlier if dose exceeds label limits |
| Cigna | Electronic precert via eviCore/CoverMyMeds; must supply weight, dosing schedule, and prior DMARD history. | 12 months |
| Blue Cross/Blue Shield | State plans often flag Remicade as non-preferred; must document biosimilar failure or contraindication. Site-of-care policies steer doses away from hospital OP departments. | 6–12 months (varies by state) |
| CareSource | Covers originator after inadequate response to at least one preferred biosimilar; pediatric Crohn’s/UC allowed without step if failure risk is high. | 12 months |
| Health Net | Step-therapy to Avsola/Inflectra; dose-escalation >10 mg/kg or <6-week interval needs peer review. | 3–12 months by disease |
🔍 Key Access Considerations
Biosimilar step therapy – Most plans now default to Avsola® or Inflectra®; document objective failure (loss of response, antibody formation) to justify Remicade.
Site-of-Care rules – Payers may deny doses delivered in hospital infusion suites when office or ASC settings are available.
Dosing ceilings – Claims exceeding 10 mg/kg or <6-week intervals often trigger manual review.
Unit rounding & wastage – Submit JW-modifier line item for discarded milligrams to avoid recoupments.
TB & hepatitis screening – Missing labs are a leading cause of PA delay; attach results to initial and renewal requests.
💡 Trends & Insights
Biosimilar pressure intensifies – 2025 step-therapy lists from Humana, UHC and several Blues plans explicitly require a biosimilar trial before Remicade approval.
CMS TPE focus – Medicare auditors place Remicade high on Targeted Probe & Educate reviews; documentation errors can spike denial rates to 20 %+.
ePA adoption accelerating – Aetna, Cigna and OptumRx accept HL7 FHIR/278 transactions, cutting median PA turnaround to <48 h for clinics that integrate.
Prior-auth reform – OptumRx dropped annual re-auth on dozens of Part B drugs in 2025; industry observers expect other PBMs to follow, potentially easing churn.
📌 Conclusion
Navigating prior authorization for Remicade hinges on meticulous documentation and awareness of each payer’s biosimilar preference. Clinics that leverage electronic PA tools, attach required labs, and track dose limits upfront can shorten approvals to days, keep infusion chairs full and avoid costly write-offs.